Arcus Biosciences Inc Stock Research

Market Summary

USD23.13+0.04

Market Closed

0.17%

RCUS Stock Price

RCUS RSI Chart

RCUS Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

20.97

Price/Sales (Trailing)

3.87

EV/EBITDA

16.46

Price/Free Cashflow

3.88

RCUS Price/Sales (Trailing)

RCUS Profitability

EBT Margin

19.09%

Return on Equity

11.42%

Return on Assets

5.73%

Free Cashflow Yield

25.78%

RCUS Fundamentals

RCUS Revenue

Revenue (TTM)

432.8M

Revenue Y/Y

254.94%

Revenue Q/Q

25.49%

RCUS Earnings

Earnings (TTM)

79.8M

Earnings Y/Y

16.74%

Earnings Q/Q

2.57%

Price Action

52 Week Range

16.7439.75

(Low)(High)

Last 7 days

8.8%

Last 30 days

17.4%

Last 90 days

-16.7%

Trailing 12 Months

-21%

RCUS Financial Health

Current Ratio

6.21

RCUS Investor Care

Shares Dilution (1Y)

3.20%

Peers (Alternatives to Arcus Biosciences)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	135.3B	26.3B	-2.97%	16.81%	19.8	5.14	2.18%	21.86%
GILD	105.0B	27.1B	-0.99%	30.15%	31.49	3.87	-1.26%	-54.91%
MRNA	73.3B	21.4B	7.28%	27.41%	6.23	3.43	80.80%	66.62%
BIIB	41.9B	10.4B	5.85%	32.49%	14.62	4.04	-6.64%	85.32%
NBIX	10.4B	1.4B	-8.79%	49.41%	178.74	7.49	29.86%	-86.92%
MID-CAP
DNLI	3.9B	-	18.31%	0.06%	-12.88	32.03	-41.50%	-1123.42%
BEAM	3.2B	-	23.33%	-24.11%	-10.12	59.51	215916.67%	21.41%
SMALL-CAP
RCUS	1.7B	432.8M	17.41%	-21.00%	20.97	3.87	1042.97%	128.67%
BBIO	1.4B	-	35.16%	1.79%	-2.74	20.84	745.14%	12.80%
REPL	1.3B	3.1M	-3.43%	39.57%	-8.78	417.83	7.05%	-46.74%
NVAX	886.0M	1.8B	24.61%	-84.52%	-0.67	0.48	53.41%	-22.97%
FATE	574.9M	69.0M	-39.96%	-83.45%	-1.96	8.33	26.22%	-49.52%
SGMO	565.8M	112.1M	28.78%	-35.14%	-3.18	5.05	3.26%	1.99%
VXRT	142.4M	-	42.67%	-74.19%	-1.36	418.24	-71.03%	-64.56%
IBIO	6.7M	-	67.66%	-93.12%	-0.11	3.21	0.51%	-141.69%

Financials for Arcus Biosciences

Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	5.9%	433	409	391	383	38
Operating Expenses	4.5%	357	342	332	329	317
S&GA Expenses	11.1%	99	89	80	72	62
R&D Expenses	2.2%	258	252	251	256	255
EBITDA	18.3%	88	75	-281.42	58	-
EBITDA Margin	11.7%	0.20*	0.18*	-0.72*	0.15*	-
Earnings Before Taxes	18.8%	83	70	60	55	-302.05
EBT Margin	12.1%	0.19*	0.17*	-0.73*	0.14*	-
Net Income	19.6%	80	67	57	53	-278.39
Net Income Margin	12.9%	0.18*	0.16*	0.15*	0.14*	-
Free Cahsflow	-4.6%	432	452	439	-282.25	-

* denotes actual numbers (not divided by Millions)

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	-5.6%	1,394	1,477	1,543	1,592	839
Current Assets	-10.3%	1,101	1,227	1,264	1,262	545
Cash Equivalents	-20.2%	218	273	549	148	179
Net PPE	1.4%	34	33	33	32	29
Liabilities	-4.7%	695	729	747	750	297
Current Liabilities	8.0%	177	164	161	166	143
Shareholder's Equity	-6.5%	699	747	797	841	543
Retained Earnings	-15.8%	-474.90	-409.98	-343.35	-275.35	-554.72
Additional Paid-In Capital	1.6%	1,183	1,165	1,145	1,118	1,097
Accumulated Depreciation	-	18	-	-	-	-
Shares Outstanding	0.4%	72	72	72	71	70

* denotes actual numbers (not divided by Millions)

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-5.8%	446	473	464	-256.17	-243.95
Share Based Compensation	2.8%	62	61	58	55	49
Cashflow From Investing	20.3%	-440.90	-552.95	-334.75	-3.87	-23.01
Cashflow From Financing	3.8%	33	32	30	237	227

Risks for RCUS

What is the probability of a big loss on RCUS?

94.2%

Probability that Arcus Biosciences stock will be more than 20% underwater in next one year

94.2%

Probability that Arcus Biosciences stock will be more than 30% underwater in next one year.

82.5%

Probability that Arcus Biosciences stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RCUS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Arcus Biosciences was unfortunately bought at previous high price.

Drawdowns

Returns for RCUS

Cumulative Returns on RCUS

33.7%

3-Year Cumulative Returns

Which funds bought or sold RCUS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-01-26	OREGON PUBLIC EMPLOYEES RETIREMENT FUND	added	0.45	-93,429	358,571	-%
2023-01-26	State of Tennessee, Treasury Department	added	6.82	82,000	872,000	-%
2023-01-26	COMERICA BANK	reduced	-21.87	-474,000	630,000	-%
2023-01-26	STRS OHIO	reduced	-19.94	-313,000	539,000	-%
2023-01-26	Inspire Investing, LLC	added	44.81	30,186	236,186	0.03%
2023-01-25	Versant Capital Management, Inc	reduced	-16.67	207	207	-%
2023-01-25	FIFTH THIRD BANCORP	unchanged	-	-3,248	13,752	-%
2023-01-24	NATIONAL BANK OF CANADA /FI/	unchanged	-	-933	2,067	-%
2023-01-24	Louisiana State Employees Retirement System	unchanged	-	-136,000	513,000	0.01%
2023-01-23	Allspring Global Investments Holdings, LLC	reduced	-6.27	-89,210	255,790	-%

Latest Funds Activity

Are funds buying RCUS calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own RCUS

No. of Funds

Arcus Biosciences News

Schedule 13G FIlings of Arcus Biosciences

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 26, 2023	blackrock inc.	13.0%	9,389,048	SC 13G/A
Jan 20, 2023	blackrock inc.	13.0%	9,389,048	SC 13G/A
Oct 17, 2022	pfm health sciences, lp	5.5%	6	SC 13G
May 09, 2022	blackrock inc.	11.1%	7,967,677	SC 13G
Mar 14, 2022	biotechnology value fund l p	3.0%	2,156,510	SC 13G
Feb 14, 2022	gv 2016, l.p.	0.91%	638,967	SC 13G/A
Feb 14, 2022	pfm health sciences, lp	4.9%	6	SC 13G/A
Feb 14, 2022	ecor1 capital, llc	7.9%	5,523,358	SC 13G/A
Feb 04, 2022	blackrock inc.	5.9%	4,129,929	SC 13G
Jul 19, 2021	ecor1 capital, llc	6.4%	4,572,047	SC 13G

RCUS Fair Value

Recent SEC filings of Arcus Biosciences

View All Filings

Date Filed	Form Type	Document
Jan 26, 2023	SC 13G/A	Major Ownership Report
Jan 25, 2023	4	Insider Trading
Jan 25, 2023	4	Insider Trading
Jan 25, 2023	4	Insider Trading
Jan 25, 2023	4	Insider Trading
Jan 25, 2023	4	Insider Trading
Jan 25, 2023	4	Insider Trading
Jan 20, 2023	SC 13G/A	Major Ownership Report
Dec 19, 2022	8-K	Current Report
Dec 16, 2022	4	Insider Trading

Latest Insider Trading transactions for RCUS

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-01-23	ROSEN TERRY J	acquired	-	-	105,700	chief executive officer
2023-01-23	Goeltz II Robert C.	acquired	-	-	34,000	chief financial officer
2023-01-23	Jarrett Jennifer	acquired	-	-	45,800	chief operating officer
2023-01-23	Nuyten Dimitry SA	acquired	-	-	34,000	chief medical officer
2023-01-23	Tang Carolyn C.	acquired	-	-	34,000	general counsel
2023-01-23	Jaen Juan C.	acquired	-	-	45,800	president
2022-12-16	ROSEN TERRY J	sold	-401,073	30.75	-13,043	chief executive officer
2022-12-16	Goeltz II Robert C.	sold	-75,429.6	30.7499	-2,453	chief financial officer
2022-12-16	Jarrett Jennifer	sold	-506,822	30.75	-16,482	chief operating officer
2022-12-16	Jaen Juan C.	sold	-136,407	30.7501	-4,436	president

About Arcus Biosciences

Terry J. Rosen

www.arcusbio.com

370

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

RCUS Income Statement

2022-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Total revenues	$ 33,581	$ 9,461	$ 78,345	$ 28,383
Operating expenses:
Research and development (($26,560), ($756), ($92,667) and ($6,856) from a related party)	76,684	71,254	207,800	206,412
General and administrative (($493), $0, ($690) and $0 from a related party)	26,294	16,343	76,104	48,990
Total operating expenses	102,978	87,597	283,904	255,402
Loss from operations	(69,397)	(78,136)	(205,559)	(227,019)
Non-operating income (expense):
Interest and other income, net	5,013	161	8,456	481
Effective interest on liability for sale of future royalties	(535)		(1,437)
Total non-operating income, net	4,478	161	7,019	481
Net loss before income taxes	(64,919)	(77,975)	(198,540)	(226,538)
Income tax expense	0	0	(1,004)	0
Net loss	(64,919)	(77,975)	(199,544)	(226,538)
Other comprehensive loss	(2,557)	(46)	(8,540)	(136)
Comprehensive loss	$ (67,476)	$ (78,021)	$ (208,084)	$ (226,674)
Net loss per share, basic	$ (0.90)	$ (1.11)	$ (2.78)	$ (3.28)
Net loss per share, diluted	$ (0.90)	$ (1.11)	$ (2.78)	$ (3.28)
Weighted-average number of shares used to compute basic net loss per share	72,236,283	70,110,138	71,752,246	68,990,290
Weighted-average number of shares used to compute diluted net loss per share	72,236,283	70,110,138	71,752,246	68,990,290
License and Development Services Revenue
Revenues:
Total revenues	$ 23,742		$ 48,374
Other Collaboration Revenue
Revenues:
Total revenues	$ 9,839	$ 9,461	$ 29,971	$ 28,383

RCUS Balance Sheet

2022-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 217,647		$ 147,914
Short-term investments	831,135		351,394
Receivable from collaboration partners ($26,521 and $744,535 from a related party)	27,286		744,595
Accrued interest receivable	3,423		2,227
Prepaid expenses and other current assets	21,625		15,620
Total current assets	1,101,116		1,261,750
Long-term investments	143,138		181,990
Property and equipment, net	33,892		32,455
Right-of-use assets	102,073		104,968
Restricted cash	3,005		3,005
Other long-term assets ($1,856 and $0 from a related party)	10,598		7,730
Total assets	1,393,822		1,591,898
Current liabilities:
Accounts payable	10,546		10,261
Accrued research and development	39,827		29,587
Other accrued liabilities	20,528		24,181
Deferred revenue, current ($103,291 and $96,981 to a related party)	103,291		102,003
Other current liabilities	2,984		52
Total current liabilities	177,176		166,084
Deferred revenue, noncurrent ($382,584 and $462,217 to a related party)	382,584		462,217
Operating lease liabilities, noncurrent	119,195		116,887
Other long-term liabilities	16,166		5,260
Total liabilities	695,121		750,448
Commitments (Note 11)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding	0		0
Common stock, $0.0001 par value, 400,000,000 shares authorized; 72,352,380 and 70,781,736 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively. Shares outstanding includes zero and 9,946 shares issued but subject to vesting as of September 30, 2022 and December 31, 2021, respectively	7		7
Additional paid-in capital	1,183,393		1,118,058
Accumulated deficit	(474,898)		(275,354)
Accumulated other comprehensive loss	(9,801)		(1,261)
Total stockholders’ equity	698,701	$ 747,386	841,450
Total liabilities and stockholders’ equity	$ 1,393,822		$ 1,591,898